The Biomedical Prevention Implementation Collaborative (BioPIC)
A collaborative approach to HIV prevention product introduction
The pipeline for HIV prevention products holds the potential to curb HIV incidence. But we know from previous products that translating trial efficacy to population impact is challenging without coordinated effort. The Biomedical Prevention Implementation Collaborative is pioneering an innovative, integrated and adaptable approach to product introduction, with a focus on injectable cabotegravir (CAB) for PrEP.
BioPIC developed the Adaptable Product Introduction Framework for all stakeholders involved in product introduction, from clinical research to rollout in low- and middle-income countries. The framework prioritizes activities that must begin in parallel to phase III clinical trials. Stakeholders with a role in early phase product development may also benefit from these considerations with better coordination around anticipated needs.
Resources
- Shaping and Coordinating the Implementation Science Agenda for Injectable Cabotegravir for PrEP: The role of the Biomedical Prevention Implementation Collaborative (BioPIC)
- Adaptable Product Introduction Framework
- Integrated Study Tracker
Think Tanks
An ongoing series of think tanks, conducted by BioPIC, are generating key insights for people-centered product delivery.
Coordinating Implementation Science for CAB for PrEP: Early Insights from EBONI and PILLAR
February 2024
ViiV Healthcare, the manufacturer of CAB for PrEP, shared early insights from their two CAB for PrEP implementation studies, the EBONI and PILLAR studies.
Learn more.
Coordinating Implementation Science for CAB for PrEP: Linking Modellers with the Latest
Implementation Science Evidence
September 2023
At this meeting, modellers of CAB for PrEP and implementation science study leads aligned on data and evidence needs to fill CAB for PrEP evidence gaps.
Learn more.
Coordinating Implementation Science for CAB for PrEP: Inclusion of Key Populations
September 2023
This meeting, part of the BioPIC implementation science series, focused on strategies to include trans and gender diverse people, gay and bisexual men who have sex with men, sex workers, and people who use and inject drugs in implementation science projects as well as the rollout and scale-up of CAB for PrEP.
Learn more.
Coordinating Implementation Science for CAB for PrEP: Bridging from the HPTN 083 and 084 Open Label Extensions to Implementation
March 2023
This fourth meeting of the BioPIC implementation science series focused on lessons learnt from the HPTN 083 and 084 Open Label Extensions.
Learn more.
Shaping and Strengthening Markets for a New Era of Choice-based HIV/SRH Programming: Lessons from HIV & FP product introduction
March 2023
As new HIV prevention products move closer to entering the market, there is an opportunity to design choice-based programs that apply lessons and successes from HIV and FP product introduction and push the envelope with new innovations. Yet delivery of biomedical HIV prevention options within FP settings remains nascent, despite a sharp rise in uptake of oral PrEP globally. Under BioPIC, AVAC and WHO convened a Think Tank with donors, implementing partners and advocates to discuss how to effectively grow and strengthen choice-based prevention markets in order to meet the diverse and comprehensive health needs of various populations.
Learn more.
Coordinating Implementation Science for CAB for PrEP: Focus on Research and Surveillance during Pregnancy and Breastfeeding
November 2022
This third meeting of the BioPIC implementation science series focused on CAB for PrEP implementation research and surveillance during pregnancy and breastfeeding.
Learn more.
Coordinating Implementation Science for CAB for PrEP: Focus on Delivery Models
June 2022
This second meeting of the BioPIC implementation science series focused on how CAB for PrEP can be integrated into existing community, pharmacy and facility-based delivery for HIV prevention.
Learn more.
Generating Demand for HIV Biomedical Prevention in the Era of Choice
June 2022
In light of the emerging need to (re-)define how to generate demand for choice in HIV biomedical prevention, AVAC, under BioPIC, convened program implementers; social and behavioural change communication, marketing, and design thinking experts; behavioral economists; researchers; donors; and civil society to identify proven and promising strategies and models to more effectively reach and engage different populations. Nine experts/organizations drawn from both the HIV and family planning sectors shared insights from their previous and current demand generation interventions for different populations and geographical contexts.
Learn more.
Coordinating Implementation Science for CAB for PrEP
April 2022
As implementation studies for injectable CAB for PrEP are being considered and as programs shift towards choice-based models for HIV prevention, there is a chance to correct for missed opportunities with oral PrEP rollout, understand client preferences and patterns of use, and ensure more effective coordination across geographies, populations, and projects. To facilitate this coordination, AVAC and WHO convened implementers, donors, members of civil society organisations, and the developer of CAB for PrEP to share plans for implementation studies.
Learn more.
Modelling the Impact of Injectable CAB for PrEP on Drug Resistance
April 2022
An important consideration in the scale-up of injectable CAB for PrEP is the potential for development of Integrase Strand Transfer Inhibitor (INSTI) resistance. To help stakeholders understand this issue further, Professor Andrew Phillips from University College London shared the results of an exercise modelling the impact of the introduction of CAB for PrEP on INSTI resistance and AIDS-related mortality, as well as cost-effectiveness.
Learn more.
HIV Testing and Injectable CAB for PrEP Introduction: What are the implications for HIV prevention scale-up and the HIV response?
December 2021
One challenge which has emerged with the introduction of CAB for PrEP is the risk of INSTI resistance amongst people who acquire HIV while taking CAB as prescribed. To address emerging evidence around testing algorithms and INSTI resistance in CAB users, AVAC and WHO convened a think tank with program implementers, testing experts, mathematical modelers, policy makers, donors, and civil society.
Learn more.
Product Introduction/Implementation Project Planning for Next-Generation PrEP
September 2021
Early data from clinical trials has indicated that CAB for PrEP is safe and effective. With an accelerated timeline for introduction of CAB for PrEP, AVAC and WHO convened a think tank to strategize about demonstration projects and other planning for product introduction.
Learn more.